CASTLE BIOSCIENCES INC (CSTL) Stock Fundamental Analysis
USA - NASDAQ:CSTL - US14843C1053 - Common Stock
24.41 USD
+0.95 (+4.05%)
24.16 USD
-0.25 (-1.02%)
We assign a fundamental rating of 5 out of 10 to CSTL. CSTL was compared to 101 industry peers in the Health Care Providers & Services industry. CSTL has a great financial health rating, but its profitability evaluates not so good. CSTL is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CSTL had positive earnings in the past year.
In the past year CSTL had a positive cash flow from operations.
In the past 5 years CSTL reported 4 times negative net income.
In multiple years CSTL reported negative operating cash flow during the last 5 years.
1.2 Ratios
CSTL has a Return On Assets of -1.74%. This is comparable to the rest of the industry: CSTL outperforms 40.59% of its industry peers.
CSTL's Return On Equity of -2.08% is in line compared to the rest of the industry. CSTL outperforms 48.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.74% | ||
| ROE | -2.08% | ||
| ROIC | N/A |
ROA(3y)-8.08%
ROA(5y)-6.67%
ROE(3y)-9.16%
ROE(5y)-7.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Profit Margin of CSTL has remained more or less at the same level.
In the last couple of years the Operating Margin of CSTL has declined.
With an excellent Gross Margin value of 81.00%, CSTL belongs to the best of the industry, outperforming 94.06% of the companies in the same industry.
In the last couple of years the Gross Margin of CSTL has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for CSTL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 81% |
OM growth 3YN/A
OM growth 5Y-28.6%
PM growth 3YN/A
PM growth 5Y-1.01%
GM growth 3Y-0.54%
GM growth 5Y-0.96%
2. Health
2.1 Basic Checks
CSTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
CSTL has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CSTL has more shares outstanding
The debt/assets ratio for CSTL is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 5.34 indicates that CSTL is not in any danger for bankruptcy at the moment.
CSTL has a Altman-Z score of 5.34. This is amongst the best in the industry. CSTL outperforms 84.16% of its industry peers.
CSTL has a debt to FCF ratio of 0.30. This is a very positive value and a sign of high solvency as it would only need 0.30 years to pay back of all of its debts.
CSTL's Debt to FCF ratio of 0.30 is amongst the best of the industry. CSTL outperforms 93.07% of its industry peers.
CSTL has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
With an excellent Debt to Equity ratio value of 0.02, CSTL belongs to the best of the industry, outperforming 83.17% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.3 | ||
| Altman-Z | 5.34 |
ROIC/WACCN/A
WACC8.77%
2.3 Liquidity
A Current Ratio of 6.85 indicates that CSTL has no problem at all paying its short term obligations.
CSTL's Current ratio of 6.85 is amongst the best of the industry. CSTL outperforms 96.04% of its industry peers.
CSTL has a Quick Ratio of 6.69. This indicates that CSTL is financially healthy and has no problem in meeting its short term obligations.
CSTL's Quick ratio of 6.69 is amongst the best of the industry. CSTL outperforms 96.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.85 | ||
| Quick Ratio | 6.69 |
3. Growth
3.1 Past
CSTL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 357.14%, which is quite impressive.
The Earnings Per Share has been growing by 29.69% on average over the past years. This is a very strong growth
The Revenue has grown by 20.41% in the past year. This is a very strong growth!
CSTL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 44.95% yearly.
EPS 1Y (TTM)357.14%
EPS 3YN/A
EPS 5Y29.69%
EPS Q2Q%-51.61%
Revenue 1Y (TTM)20.41%
Revenue growth 3Y52.25%
Revenue growth 5Y44.95%
Sales Q2Q%-0.94%
3.2 Future
CSTL is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -32.79% yearly.
Based on estimates for the next years, CSTL will show a small growth in Revenue. The Revenue will grow by 4.31% on average per year.
EPS Next Y-395.59%
EPS Next 2Y-123.55%
EPS Next 3Y-70.43%
EPS Next 5Y-32.79%
Revenue Next Year-3.02%
Revenue Next 2Y-2.15%
Revenue Next 3Y1.44%
Revenue Next 5Y4.31%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 67.81, the valuation of CSTL can be described as expensive.
The rest of the industry has a similar Price/Earnings ratio as CSTL.
The average S&P500 Price/Earnings ratio is at 27.38. CSTL is valued rather expensively when compared to this.
CSTL is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 67.81 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CSTL is valued a bit cheaper than the industry average as 61.39% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, CSTL is valued a bit cheaper than 62.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.5 | ||
| EV/EBITDA | 12.81 |
4.3 Compensation for Growth
A cheap valuation may be justified as CSTL's earnings are expected to decrease with -70.43% in the coming years.
PEG (NY)N/A
PEG (5Y)2.28
EPS Next 2Y-123.55%
EPS Next 3Y-70.43%
5. Dividend
5.1 Amount
No dividends for CSTL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
24.41
+0.95 (+4.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners92.95%
Inst Owner Change4.53%
Ins Owners2.76%
Ins Owner Change1.96%
Market Cap708.13M
Analysts88.57
Price Target36.34 (48.87%)
Short Float %5.39%
Short Ratio2.86
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-23.82%
Min EPS beat(2)-175.74%
Max EPS beat(2)128.1%
EPS beat(4)3
Avg EPS beat(4)183.56%
Min EPS beat(4)-175.74%
Max EPS beat(4)558.79%
EPS beat(8)7
Avg EPS beat(8)146.14%
EPS beat(12)10
Avg EPS beat(12)99.67%
EPS beat(16)12
Avg EPS beat(16)80.49%
Revenue beat(2)2
Avg Revenue beat(2)12.85%
Min Revenue beat(2)7.37%
Max Revenue beat(2)18.34%
Revenue beat(4)4
Avg Revenue beat(4)8.59%
Min Revenue beat(4)3.31%
Max Revenue beat(4)18.34%
Revenue beat(8)8
Avg Revenue beat(8)13.11%
Revenue beat(12)12
Avg Revenue beat(12)10.99%
Revenue beat(16)16
Avg Revenue beat(16)10.02%
PT rev (1m)-1.35%
PT rev (3m)-0.74%
EPS NQ rev (1m)6.22%
EPS NQ rev (3m)16.27%
EPS NY rev (1m)0%
EPS NY rev (3m)-22.39%
Revenue NQ rev (1m)0.73%
Revenue NQ rev (3m)6.49%
Revenue NY rev (1m)0.93%
Revenue NY rev (3m)7.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 67.81 | ||
| Fwd PE | N/A | ||
| P/S | 2.05 | ||
| P/FCF | 20.5 | ||
| P/OCF | 11.33 | ||
| P/B | 1.56 | ||
| P/tB | 2.02 | ||
| EV/EBITDA | 12.81 |
EPS(TTM)0.36
EY1.47%
EPS(NY)-1.89
Fwd EYN/A
FCF(TTM)1.19
FCFY4.88%
OCF(TTM)2.15
OCFY8.82%
SpS11.94
BVpS15.7
TBVpS12.11
PEG (NY)N/A
PEG (5Y)2.28
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.74% | ||
| ROE | -2.08% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 81% | ||
| FCFM | 9.97% |
ROA(3y)-8.08%
ROA(5y)-6.67%
ROE(3y)-9.16%
ROE(5y)-7.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y-28.6%
PM growth 3YN/A
PM growth 5Y-1.01%
GM growth 3Y-0.54%
GM growth 5Y-0.96%
F-Score4
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.3 | ||
| Debt/EBITDA | 0.44 | ||
| Cap/Depr | 65.78% | ||
| Cap/Sales | 8.07% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 321.49% | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.85 | ||
| Quick Ratio | 6.69 | ||
| Altman-Z | 5.34 |
F-Score4
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)113.65%
Cap/Depr(5y)290.73%
Cap/Sales(3y)6.28%
Cap/Sales(5y)6.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)357.14%
EPS 3YN/A
EPS 5Y29.69%
EPS Q2Q%-51.61%
EPS Next Y-395.59%
EPS Next 2Y-123.55%
EPS Next 3Y-70.43%
EPS Next 5Y-32.79%
Revenue 1Y (TTM)20.41%
Revenue growth 3Y52.25%
Revenue growth 5Y44.95%
Sales Q2Q%-0.94%
Revenue Next Year-3.02%
Revenue Next 2Y-2.15%
Revenue Next 3Y1.44%
Revenue Next 5Y4.31%
EBIT growth 1Y-46.28%
EBIT growth 3YN/A
EBIT growth 5Y3.5%
EBIT Next Year-26.07%
EBIT Next 3Y-123.63%
EBIT Next 5Y-26.67%
FCF growth 1Y166.87%
FCF growth 3YN/A
FCF growth 5Y43.14%
OCF growth 1Y254.44%
OCF growth 3YN/A
OCF growth 5Y56%